Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

23.53
-1.1700-4.74%
Post-market: 23.530.00000.00%18:46 EDT
Volume:294.10K
Turnover:7.01M
Market Cap:699.58M
PE:-28.23
High:24.65
Open:24.60
Low:23.44
Close:24.70
52wk High:44.28
52wk Low:14.59
Shares:29.73M
Float Shares:25.11M
Volume Ratio:0.97
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8334
EPS(LYR):-0.8334
ROE:-5.21%
ROA:-2.56%
PB:1.49
PE(LYR):-28.23

Loading ...

Castle Biosciences to present new data from DecisionDx-Melanoma test at AAD

TIPRANKS
·
Mar 27

Castle Biosciences CEO Derek J. Maetzold disposes of USD 500,438 in common shares

Reuters
·
Mar 20

Castle Biosciences CEO Derek J. Maetzold disposes of USD 784,000 in common shares

Reuters
·
Mar 18

Castle Biosciences Chief Commercial Officer Juvenal Tobin W disposes of USD 526,000 in common shares

Reuters
·
Mar 17

Castle Biosciences CEO Derek J. Maetzold Disposes of Common Shares

Reuters
·
Mar 14

Castle announces publication of DecisionDx-Melanoma’s i31-SLNB study results

TIPRANKS
·
Mar 13

Castle Biosciences study links DecisionDx-Melanoma i31-SLNB low-risk result to 3% sentinel node positivity and 98% three-year recurrence-free survival

Reuters
·
Mar 13

SciBase Q4 net sales rose 45% to SEK 12.48 million

Reuters
·
Mar 13

Sweden's SciBase Q4 sales rise on US, skin barrier growth

Reuters
·
Mar 13

Decisiondx®-Melanoma’s I31-Slnb: Report From the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

THOMSON REUTERS
·
Mar 09

Castle Biosciences CFO Frank Stokes Disposes of Common Shares

Reuters
·
Mar 06

Castle Biosciences to Present DecisionDx-Melanoma i31-SLNB Data at SSO 2026 Annual Meeting

Reuters
·
Mar 05

Castle Biosciences Is Maintained at Outperform by Baird

Dow Jones
·
Feb 27

Guggenheim Remains a Buy on Castle Biosciences (CSTL)

TIPRANKS
·
Feb 27

Castle Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 27

Castle Biosciences Q4 revenue beats expectations

Reuters
·
Feb 27

BRIEF-Castle Biosciences Q4 Revenue USD 87.01 Million Vs. IBES Estimate USD 79 Million

Reuters
·
Feb 27

Castle Biosciences Inc: Anticipates Generating Between $340-350 Million in Total Revenue in 2026

THOMSON REUTERS
·
Feb 27

Castle Biosciences Q4 Operating Expenses USD 90.837 Million

THOMSON REUTERS
·
Feb 27

JAAD study validates Castle Biosciences’ AdvanceAD-Tx test for guiding JAK inhibitor response in atopic dermatitis

Reuters
·
Feb 20